PSMA-targeted radioactive therapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a radioactive treatment called 177Lu-PSMA-617 for advanced liver cancer that has not responded to first-line immunotherapy. You need a PSMA-PET scan first to see if your cancer absorbs the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your liver cancer has spread beyond the liver (metastatic) or cannot be removed completely.
- You have already received one line of immunotherapy for your liver cancer (like an anti-PD-L1 drug).
- You are 18 years or older and have a good performance status (ECOG 0-1).
- Your liver function is well enough (Child-Pugh class A or B7) and your blood counts, kidney function are okay.
- A special scan (PSMA-PET) shows that your cancer takes up the imaging tracer.
- You are not pregnant, breastfeeding, or planning a pregnancy, and you will use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of focused radiation (SBRT) and a targeted radioactive drug (Lutetium PSMA) for men with prostate cancer that has spread to nearby lymph nodes or has high-risk features but has not yet reached distant organs. The goal is to see if this approach is safe and effective.
This trial tests whether giving a higher first dose of a radioactive drug (Lu-177-PSMA-617) can better treat prostate cancer that has spread and no longer responds to hormone therapy. The drug targets cancer cells and delivers radiation directly to them.
This trial tests a targeted radiation drug (Lu177-PSMA) combined with procedures that treat liver tumors directly (like ablation or radiation). It is for men with prostate cancer that has spread to the liver and is no longer responding to hormone therapy. The goal is to see if this combination works better together.
This trial tests a radioactive treatment (called radiopharmaceutical) that targets a protein called PSMA on kidney cancer cells. It is for people with advanced clear cell kidney cancer that has already been treated with immunotherapy and targeted therapy.
This study tests a radioactive drug called Lu-PSMA-617 for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly to the tumor.
This trial tests a radioactive drug called Lutetium-177 (Lu-177) that targets and kills prostate cancer cells showing a specific marker (PSMA). It's for men with advanced prostate cancer that has spread and stopped responding to hormone therapy, and who have already tried certain chemotherapy or cannot have it.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.